Axsome Therapeutics (AXSM) Receivables (2022 - 2026)

Axsome Therapeutics has disclosed Receivables across 5 years of filings, most recently posting $251.1 million for Q1 2026.

• Receivables for Q1 2026 came in at $251.1 million, up 55.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $251.1 million (up 55.55% YoY), and the FY2025 annual result was $224.5 million, up 44.35% from the prior year.
• Receivables came in at $251.1 million for Q1 2026 at Axsome Therapeutics, up from $224.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $251.1 million in Q1 2026 to a low of $16.2 million in Q2 2022.
• The 5-year median for Receivables is $117.7 million (2024), against an average of $123.1 million.
• Across the five-year window, Receivables soared 413.75% in 2023 and surged 40.2% in 2025, its largest moves.
• Axsome Therapeutics' Receivables stood at $37.7 million in 2022, then surged by 184.68% to $107.3 million in 2023, then surged by 44.9% to $155.5 million in 2024, then soared by 44.35% to $224.5 million in 2025, then advanced by 11.85% to $251.1 million in 2026.
• The last three Receivables figures came in at $251.1 million (Q1 2026), $224.5 million (Q4 2025), and $196.5 million (Q3 2025), per Business Quant data.